Stay updated with breaking news from Leukemia Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Lindsay Wilde, MD, explains when cannabis may be appropriate and how she’s seen the agent affect quality of life for her patients.
LYT-200 is being advanced in hematological malignancies such as acute myeloid leukemia and high-risk myelodysplastic syndrome , and locally advanced/metastatic solid tumors, including head and neck...
The FDA has granted orphan drug designation to LYT-200 for the treatment of acute myeloid leukemia.
Andrew Evens, DO, MBA, MSc, highlights key points presented during the 2023 Rutgers Cancer Institute of New Jersey’s Annual Oncology Clinical Practice and Research Summit, the clinical implications of these presentations, and lymphoma treatment innovations that Rutgers Cancer Institute is providing to patients throughout New Jersey.
The addition of quizartinib to induction and consolidation chemotherapy, followed by single-agent quizartinib for up to 36 cycles, improved survival outcomes vs placebo in patients with FLT3 ITD–mutated, newly diagnosed acute myeloid leukemia.